Roivant Sciences (NASDAQ:ROIV) Upgraded at Cantor Fitzgerald

Roivant Sciences (NASDAQ:ROIV - Get Free Report) was upgraded by research analysts at Cantor Fitzgerald to a "strong-buy" rating in a research note issued on Tuesday,Zacks.com reports.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $18.08.

Roivant Sciences Trading Up 0.4 %

Shares of ROIV traded up $0.04 during midday trading on Tuesday, reaching $10.64. 4,266,155 shares of the company were exchanged, compared to its average volume of 4,417,301. Roivant Sciences has a 1-year low of $9.76 and a 1-year high of $13.06. The stock has a 50-day moving average price of $10.93 and a 200-day moving average price of $11.55. The company has a market cap of $7.59 billion, a price-to-earnings ratio of -70.93 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts anticipate that Roivant Sciences will post -0.92 earnings per share for the current year.

Remove Ads

Insider Buying and Selling at Roivant Sciences

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm's stock in a transaction dated Monday, January 13th. The stock was bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the transaction, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CIO Mayukh Sukhatme sold 412,584 shares of the firm's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total value of $4,971,637.20. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at $226,980,391.35. This trade represents a 2.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,388,170 shares of company stock worth $27,612,299 in the last ninety days. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ROIV. Russell Investments Group Ltd. lifted its holdings in Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after acquiring an additional 1,948 shares during the last quarter. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences during the 3rd quarter worth approximately $35,000. US Bancorp DE grew its stake in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after buying an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in Roivant Sciences during the 4th quarter worth $39,000. Finally, GAMMA Investing LLC lifted its stake in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after buying an additional 1,288 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.